483 related articles for article (PubMed ID: 19454711)
1. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
2. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
Murray HW; Delph-Etienne S
J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
[TBL] [Abstract][Full Text] [Related]
3. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
5. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
6. Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production.
Forget G; Gregory DJ; Whitcombe LA; Olivier M
Infect Immun; 2006 Nov; 74(11):6272-9. PubMed ID: 17057094
[TBL] [Abstract][Full Text] [Related]
7. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
Verma NK; Singh G; Dey CS
Exp Parasitol; 2007 May; 116(1):1-13. PubMed ID: 17161839
[TBL] [Abstract][Full Text] [Related]
8. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
10. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
11. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.
Seifert K; Escobar P; Croft SL
J Antimicrob Chemother; 2010 Mar; 65(3):508-11. PubMed ID: 20089542
[TBL] [Abstract][Full Text] [Related]
13. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
14. RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages.
Flandin JF; Chano F; Descoteaux A
Eur J Immunol; 2006 Feb; 36(2):411-20. PubMed ID: 16369915
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-7 potentiates MAPK10-elicited host-protective vaccine against Leishmania donovani.
Kumar S; Bodhale N; Patra SK; Sarode A; Zhao L; Sarkar A; Saha B
Cytokine; 2024 Feb; 174():156475. PubMed ID: 38134556
[TBL] [Abstract][Full Text] [Related]
16. Isolation of protective T cells from BALB/cJ mice chronically infected with Leishmania donovani.
Holaday B; Sadick MD; Pearson RD
J Immunol; 1988 Sep; 141(6):2132-7. PubMed ID: 3262649
[TBL] [Abstract][Full Text] [Related]
17. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
18. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
[TBL] [Abstract][Full Text] [Related]
19. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of interferon-gamma signaling by Leishmania donovani.
Ray M; Gam AA; Boykins RA; Kenney RT
J Infect Dis; 2000 Mar; 181(3):1121-8. PubMed ID: 10720539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]